poudre pour solution injectable (IM-IV)

DRUG4 trials

Sponsors

Lysarc, Assistance Publique Hopitaux De Paris, Centre Hospitalier De Versailles, Centre Hospitalier Universitaire De Nantes

Conditions

COPD : chronic obstructive Pulmonary diseaseCommunity-acquired pneumoniaPeripheral T-cell lymphoma (PTCL)staphylococcal endocarditis

Phase 3

CUSTOMIZED ANTIBIOTIC TREATMENT DURATION AMONG HOSPITALIZED PATIENTS WITH MODERATELY SEVERE COMMUNITY-ACQUIRED PNEUMONIA [CAT-CAP]

RecruitingCTIS2023-504208-27-00

Assistance Publique Hopitaux De ParisCommunity-acquired pneumonia

Start: 2024-02-12Target: 424Updated: 2025-04-10

CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients in the intensive care unit: a multicentre randomized controlled trial

Active, not recruitingCTIS2024-516651-41-00

Centre Hospitalier De VersaillesCOPD : chronic obstructive Pulmonary disease

Start: 2021-10-08Target: 440Updated: 2025-09-23

Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)

Not yet recruitingCTIS2024-518018-22-00

Centre Hospitalier Universitaire De Nantesstaphylococcal endocarditis

Target: 422Updated: 2025-08-28

Phase 4

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

RecruitingCTIS2022-501710-62-02

LysarcPeripheral T-cell lymphoma (PTCL)

Start: 2023-06-07Target: 204Updated: 2026-01-19